Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atrial Fibrillation
22 janv. 2025 17h00 HE
|
Anthos Therapeutics
Secondary endpoints also showed a highly significant 67% reduction in major bleeding and an 89% reduction in gastrointestinal (GI) bleeding The company’s AZALEA-TIMI 71 study is the longest...
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
16 nov. 2024 16h38 HE
|
Anthos Therapeutics
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy taking abelacimab as compared to rivaroxaban AZALEA-TIMI 71...
Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
31 oct. 2024 08h00 HE
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer
10 oct. 2024 08h00 HE
|
Anthos Therapeutics
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (“Anthos”), a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the...
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
06 juin 2024 08h15 HE
|
Anthos Therapeutics
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
22 avr. 2024 11h09 HE
|
Anthos Therapeutics
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by...
Anthos Therapeutics Supported Global Survey of 3000+ Patients Prescribed Anticoagulants Detailing Impact of Patient-Relevant Bleeding (PRB) Presented at ISTH 2023
26 juin 2023 07h00 HE
|
Anthos Therapeutics
Patient-Centric Survey Conducted in Collaborationwith StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology,...
中国および日本の規制当局、アンソス･セラピューティクス (Anthos Therapeutics) の第XI/XIa因子二重阻害剤「アベラシマブ (Abelacimab)」の治験を承認
09 juin 2023 06h18 HE
|
Anthos Therapeutics
心房細動の中国人の患者で抗凝固剤を処方されているのは26％未満であり、また、日本のがん患者の3分の1近くは、十分な治療を受けていない 中国のがん患者の約63％が最初に診断を受けてから6ヶ月以内に静脈血栓塞栓症を発症 アベラシマブはすでに北米、欧州、アジア太平洋地域のその他の諸国の、23ヶ国で試験中 マサチューセッツ州ケンブリッジ発, June 09, 2023 (GLOBE...
Les autorités réglementaires chinoises et japonaises approuvent les essais cliniques sur l'abelacimab, un inhibiteur du facteur XI/XIa à double action d'Anthos Therapeutics
09 juin 2023 06h18 HE
|
Anthos Therapeutics
Moins de 26 % des patients chinois souffrant de fibrillation auriculaire se voient prescrire un anticoagulant, tandis qu'au Japon, près d'un tiers des patients sont insuffisamment traités Environ...
Zulassungsbehörden in China und Japan genehmigen klinische Studien für doppelt wirkenden Faktor XI/XIa-Inhibitor Abelacimab von Anthos Therapeutics
09 juin 2023 06h18 HE
|
Anthos Therapeutics
Weniger als 26 % der chinesischen Patienten mit Vorhofflimmern bekommen einen Gerinnungshemmer verschrieben, während in Japan fast ein Drittel der Patienten unterbehandelt wird Ungefähr 63 % der...